High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study Laura Andrés; Marisa Iborra; Raquel Vicente; Lara Arias; Pilar Nos; Ana Royo-Esteban; Beatriz Sicilia;

Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series Marta Romero-Gutiérrez; Sonia Pascual; Laura Márquez; Mariano Gómez-Rubio; Mireia Miquel; Cristina Alarcón; Teresa Ferrer; Carles Aracil; Diana Horta; Raquel Latorre; Jesús González Santiago; Vanesa Bernal; Cristina Fernández; Belén Piqueras; María Luisa Gutiérrez; Ana Martín; Julia Morillas; Dalia Morales; Sonia Blanco; Paloma Rendón; Inmaculada Chico; Milagros Testillano; Carolina Delgado; Ana Matilla; Rafael Gómez Rodríguez;

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study Juan Turnes; Diego Rincón; José L. Calleja; Manuel B. Delgado; José M. Rosales; Raúl J. Andrade; María L. Manzano; Francisco J. Salmerón; María A. López; Marta Calvo; Judith Gómez; Esther Molina; Yza Nubia Frias; Roque Miguel Gálvez-Fernández; Nicolau Vallejo-Senra; Sara París; Regina Santos de Lamadrid; Antonio Olveira;